Anti-PD-L1 antibody [BLR020E] (ab243877)

Rabbit Recombinant Monoclonal PD-L1 antibody. Suitable for IHC-P, IP, WB, ICC/IF and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human CD274 aa 250 to C-terminus.

Be the first to review this product! Submit a review

Images

Immunoprecipitation - Anti-PD-L1 antibody [BLR020E] (AB243877), expandable thumbnail

Publications

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.8 - 8.6
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline, 0.1% BSA
Form: Liquid
Clonality: Monoclonal

Immunogen

Synthetic Peptide within Human CD274 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link Q9NZQ7

Reactivity data

Select an application

Product promiseTestedExpectedPredictedNot recommended

	IHC-P	IP	WB	ICC/IF
Human	Tested	Tested	Tested	Tested

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info 1/100 - 1/500	Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes Use 20μl/mg lysate.

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info 1/1000	Notes -

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info 1/100 - 1/500	Notes -

Associated Products

Select an associated product type

8 products for Alternative Product

Target data

See full target information CD274

Function

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

Alternative names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.8 - 8.6
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline, 0.1% BSA
Form: Liquid
Clonality: Monoclonal
Immunogen: Synthetic Peptide within Human CD274 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link Q9NZQ7
Clone number: BLR020E
Concentration
Purification notes: Recombinant antibody was purified from cell culture supernatant.

Storage

Shipped at conditions: Blue Ice
Appropriate short-term storage duration: 1-2 weeks
Appropriate short-term storage conditions: +4°C
Appropriate long-term storage conditions: -20°C
Aliquoting information: Upon delivery aliquot
Storage information: Avoid freeze / thaw cycle

Notes

This product is sold under License from Bethyl Laboratories, Inc.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.

Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

Associated diseases and disorders

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

9 product images

Immunoprecipitation - Anti-PD-L1 antibody [BLR020E] (ab243877)
PD-L1 was immunoprecipitated from HeLa RKO cell lysate (1.0 mg per IP reaction, 20% loaded) with ab243877 at 20 μl/mg lysate. Western blot was performed on the immunoprecipitate using ab243877 at 1/1000 dilution.
Lane 1: rabbit anti-PD-L1 recombinant monoclonal antibody IP in RKO whole cell lysate.
Lane 2: ab243877 IP in RKO whole cell lysate.
Lane 3: ab243877 IP in RKO whole cell lysate.
Lane 4: Control IgG in RKO whole cell lysate.
Detection: Chemiluminescence with an exposure time of 10 seconds
All lanes: Immunoprecipitation - Anti-PD-L1 antibody [BLR020E] (ab243877)
Predicted band size: 33 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [BLR020E] (ab243877)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling PD-L1 with ab243877 and secondary HRP-conjugated goat anti-rabbit IgG.
Immunoprecipitation - Anti-PD-L1 antibody [BLR020E] (ab243877)
PDL-1 was immunoprecipitated from SUP-M2 whole cell lysate with ab243877. Western blot was performed on the immunoprecipitate using ab243877 at 1/1000 dilution. Lane 1: ab243877 IP in SUP-M2 whole cell lysate.
Lane 2: Contol IgG in SUP-M2 whole cell lysate.
Detection: Chemiluminescence.
All lanes: Immunoprecipitation - Anti-PD-L1 antibody [BLR020E] (ab243877)
Predicted band size: 33 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [BLR020E] (ab243877)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human Sup-M2 cells labelling PD-L1 with ab243877 and secondary HRP-conjugated goat anti-rabbit IgG.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [BLR020E] (ab243877)
Formalin-fixed, paraffin-embedded human lung carcinoma tissue stained for PD-L1 using ab243877 at 1/250 dilution in immunohistochemical analysis. A HRP-conjugated goat anti-rabbit IgG was used as the secondary. Counterstain was DAPI.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [BLR020E] (ab243877)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast carcinoma tissue labelling PD-L1 with ab243877 and HRP-conjugated goat anti-rabbit secondary. CD8 alpha is in red, and CD3E is in green. Counterstain is DAPI (blue)
Western blot - Anti-PD-L1 antibody [BLR020E] (ab243877)
Detection: chemiluminescence.
All lanes: Western blot - Anti-PD-L1 antibody [BLR020E] (ab243877) at 1/1000 dilution
Lane 1: SUP-M2 whole cell lysate at 50 µg
Lane 2: HDLM-2 whole cell lysate at 50 µg
Lane 3: HEK-293T whole cell lysate at 50 µg
Lane 4: Ramos whole cell lysate at 50 µg
Lane 5: Jurkat whole cell lysate at 50 µg
Lane 6: PD-L2 whole cell lysate at 50 µg
Lane 7: PD-L1 whole cell lysate at 50 µg
Lane 8: HEK-293 whole cell lysate at 50 µg
Secondary
All lanes: HRP-conjugated goat anti-rabbit IgG antibody
Predicted band size: 33 kDa
Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [BLR020E] (ab243877)
Formaldehyde-fixed HDML-2 cells labeling PDL-1 using Anti-PBRM1/BAF180 antibody [BL-39-2C3] ab243876 at 1/250 dilution in ICC/IF analysis. A HRP-conjugated goat anti-rabbit IgG was used as the secondary antibody. DAB staining
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [BLR020E] (ab243877)
Formalin-fixed, paraffin-embedded human lung carcinoma tissue stained for PD-L1 using ab243877 at 1/100 dilution in immunohistochemical analysis. A DyLight^®-conjugated goat anti-rabbit IgG was used as the secondary. DAB staining.